AI Engines For more Details: Perplexity Kagi Labs You
Limited Research in Humans: There is scarce research available on the health impacts of 6-FA in humans, particularly as a non-drug compound. Most of the research on 6-FA has focused on its agricultural applications and its effects on plant physiology.
Potential Effects on Cell Growth: As a cytokinin analog, 6-FA may have potential effects on cell growth and proliferation. Cytokinins are known to stimulate cell division and promote growth in plants. In theory, 6-FA could influence cell growth processes in humans, although the specific mechanisms and effects are not well understood.
Safety Concerns: Due to the limited research available, the safety profile of 6-FA in humans is not well-established. It is unclear whether 6-FA has any adverse effects or toxicity when consumed or exposed to humans. As with any synthetic chemical, there may be potential safety concerns associated with its use, particularly at higher doses or with long-term exposure.
Potential for Pharmacological Use: While 6-FA is primarily used in agriculture, there is some interest in exploring its potential pharmacological applications. Cytokinins have been studied for their potential therapeutic effects in various medical conditions, including neurodegenerative disorders, cancer, and aging-related conditions. However, research on the pharmacological properties of 6-FA in humans is limited, and further studies are needed to evaluate its efficacy and safety.
Regulatory Status: The regulatory status of 6-FA may vary depending on its intended use and jurisdiction. In some countries, it may be regulated as an agricultural chemical, while in others, it may be subject to regulations governing chemical safety and environmental protection. The use of 6-FA in non-agricultural settings may be subject to regulatory oversight to ensure safety and compliance with applicable laws and regulations.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.1 | 5 |
| ADHD | 2 | 0.6 | 2.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.4 | 1.1 | 1.18 |
| Allergies | 3.9 | 1.1 | 2.55 |
| Allergy to milk products | 1.8 | 1.3 | 0.38 |
| Alzheimer's disease | 4.1 | 4.4 | -0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 1 | 0.6 |
| Ankylosing spondylitis | 1.8 | 1.2 | 0.5 |
| Anorexia Nervosa | 1.2 | 2.6 | -1.17 |
| Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
| Asthma | 2.8 | 1.1 | 1.55 |
| Atherosclerosis | 1.9 | 1.2 | 0.58 |
| Atrial fibrillation | 2.6 | 1.9 | 0.37 |
| Autism | 4.9 | 4.9 | 0 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.7 | 1.7 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 1 | 0.3 | 2.33 |
| Cancer (General) | 0.5 | -0.5 | |
| Carcinoma | 2.2 | 1 | 1.2 |
| Celiac Disease | 2.1 | 1 | 1.1 |
| Cerebral Palsy | 0.8 | 1.1 | -0.38 |
| Chronic Fatigue Syndrome | 3.3 | 2.4 | 0.38 |
| Chronic Kidney Disease | 2.4 | 1.5 | 0.6 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.1 | 0.27 |
| Chronic Urticaria (Hives) | 1.8 | 0.7 | 1.57 |
| Coagulation / Micro clot triggering bacteria | 2 | 1.1 | 0.82 |
| Cognitive Function | 1.9 | 1 | 0.9 |
| Colorectal Cancer | 4.9 | 2.3 | 1.13 |
| Constipation | 1.2 | 0.5 | 1.4 |
| Coronary artery disease | 2.8 | 2.4 | 0.17 |
| COVID-19 | 3.4 | 4.4 | -0.29 |
| Crohn's Disease | 5.2 | 3.1 | 0.68 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.3 | 0.8 | 0.63 |
| d-lactic acidosis (one form of brain fog) | 0.7 | 0.7 | |
| deep vein thrombosis | 3.1 | 1.4 | 1.21 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 5.3 | 5.1 | 0.04 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.7 | 1.2 | 0.42 |
| Endometriosis | 2.6 | 1.8 | 0.44 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.6 | 0.8 | 2.25 |
| erectile dysfunction | 1.7 | 1.7 | |
| Fibromyalgia | 1.5 | 1.6 | -0.07 |
| Functional constipation / chronic idiopathic constipation | 4 | 2.9 | 0.38 |
| gallstone disease (gsd) | 3.5 | 0.5 | 6 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.3 | 1.33 |
| Generalized anxiety disorder | 3 | 1.6 | 0.88 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.8 | 0.13 |
| Graves' disease | 1 | 1.7 | -0.7 |
| Gulf War Syndrome | 0.8 | 0.7 | 0.14 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.9 | 0.4 | 3.75 |
| Heart Failure | 3.8 | 1.4 | 1.71 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 1.5 | 0.3 | 4 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | |
| hyperglycemia | 1.3 | 0.7 | 0.86 |
| hypertension (High Blood Pressure | 2.1 | 2.4 | -0.14 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 2.3 | 2.3 | |
| IgA nephropathy (IgAN) | 1.6 | 1.5 | 0.07 |
| Inflammatory Bowel Disease | 4.5 | 4.6 | -0.02 |
| Insomnia | 1.2 | 1.7 | -0.42 |
| Intelligence | 1.5 | 1.5 | |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 4.3 | 2.5 | 0.72 |
| ischemic stroke | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 4.9 | 2.6 | 0.88 |
| Long COVID | 3.4 | 2.5 | 0.36 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 0.3 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.5 | 0.9 | -0.8 |
| ME/CFS without IBS | 1.6 | 0.3 | 4.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.5 | -0.25 |
| Metabolic Syndrome | 5.2 | 3 | 0.73 |
| Mood Disorders | 4.7 | 5.2 | -0.11 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.4 | 3.7 | -0.54 |
| Multiple system atrophy (MSA) | 0.1 | 0.3 | -2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.3 | -3.33 |
| Neuropathy (all types) | 0.6 | 1.6 | -1.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3 | 2 | 0.5 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 4.4 | 4.3 | 0.02 |
| obsessive-compulsive disorder | 3.5 | 1.9 | 0.84 |
| Osteoarthritis | 2 | 0.9 | 1.22 |
| Osteoporosis | 2.2 | 0.6 | 2.67 |
| pancreatic cancer | 0.9 | 0.6 | 0.5 |
| Parkinson's Disease | 4.8 | 4.3 | 0.12 |
| Polycystic ovary syndrome | 4.6 | 1.9 | 1.42 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.5 | -0.67 |
| Primary sclerosing cholangitis | 1.3 | 1.8 | -0.38 |
| Psoriasis | 2.1 | 2.2 | -0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 2.6 | 0.54 |
| Rosacea | 0.4 | 0.7 | -0.75 |
| Schizophrenia | 2.8 | 2.1 | 0.33 |
| scoliosis | 1 | 0.3 | 2.33 |
| Sjögren syndrome | 1.3 | 1 | 0.3 |
| Sleep Apnea | 0.6 | 1.7 | -1.83 |
| Slow gastric motility / Gastroparesis | 1.3 | 1.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 2.1 | 1.7 | 0.24 |
| Systemic Lupus Erythematosus | 3.7 | 0.8 | 3.63 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.8 | 1.6 | 0.75 |
| Type 2 Diabetes | 5.3 | 3.7 | 0.43 |
| Ulcerative colitis | 3.3 | 2.9 | 0.14 |
| Unhealthy Ageing | 2.6 | 1.9 | 0.37 |
| Vitiligo | 2 | 1.2 | 0.67 |
